Defeat Duchenne Canada: Industry Partner Update with Dyne Therapeutics

Defeat Duchenne Canada is committed to bringing the latest in Duchenne muscular dystrophy research and drug development to you - our Canadian Duchenne community.
Our latest industry partner update was from Dyne Therapeutics, presented by Dr. Ashish Dugar, Senior Vice President of Global Medical Affairs, on Monday, February 5, 2024. Dr. Dugar provided an update on the initial clinical data, first released on January 3, 2024, from the DELIVER trial of DYNE-251 in patients with Duchenne amenable to exon 51 skipping.

[@sravanya3795]

Any trail for skipping of exon 52